Модератор: Pyankov Vasily
2015 ESC Clinical Practice Guidelines are now availablePhysical exam of future will be hand held ultrasound
Richard Popp
Heart attack patients without heart failure derive no benefit from the addition of mineralocortoid receptor antagonists (MRA), to standard therapy, results of the ALBATROSS study show.
In patients with chronic ischemic heart disease, a small left ventricle with thick walls, is the strongest predictor of morphologic remodelling, which is generally considered a first step towards heart failure, according to unexpected findings presented today at ESC Congress 2015.DOPPLER-CIP Trial
In patients with long-standing persistent atrial fibrillation (AF) despite standard treatment, additional electrical isolation of an area called the left atrial appendage (LAA) can improve freedom from AF without increasing complications, results of the BELIEF study show.
Занятия спортом, 8 часовой сон, избегать стрессов и принимать БАДы с омега-3, что еще нужно для долгой и здоровой жизни...eshkolnik писал(а):Еще на-церемонии открытия отличная лекция про взаимосзязь длины теломер депрессии и ССЗ от нобелевского лауреата.
In patients with poor blood pressure control despite treatment with a combination of three drugs (‘resistant hypertension’), addition of the diuretic spironolactone was significantly more effective than adding other blood pressure lowering drugs, according to results of the PATHWAY-2 trial.
The combination of two commonly used diuretics, each at half dose, can significantly reduce blood pressure without the side-effects caused by full doses of either alone, researchers from the PATHWAY 3 study have found.
In older patients with arthritis and no history of cardiovascular disease, chronic use of any non-steroidal anti-inflammatory drug appears safe from a cardiovascular and gastrointestinal stand-point, and regular, non-selective NSAIDs such as ibuprofen and diclofenac appear just as safe as the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib according to results the SCOT trial.
Extending clot-preventing dual antiplatelet therapy (DAPT) beyond the recommended 12 months after coronary stenting “should be considered” in patients at low risk for bleeding, investigators for the OPTIDUAL trial recommend.
Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnoea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.
Gene transfer therapy aimed at correcting an enzyme abnormality involved in myocardial contraction and relaxation did not improve outcomes in heart failure patients with reduced ejection fraction, results of the CUPID 2 study show
Absorbable Stents Prove Non-Inferior to Metal in ABSORB STEMI TROFI II trial study
A drug-eluting coronary stent, or “scaffold” made from bioresorbable material, showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.